133 results about "High insulin" patented technology

Methods of treating metabolic diseases and disorders using a FGF21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, diabetic nephropathy, neuropathy, retinopathy, ischemic heart disease, peripheral vascular disease and cerebrovascular disease

Disclosed health-care noodle capable of regulating blood sugar is prepared from the following raw materials in parts by weight: 70-80 parts of whole wheat flour, 20-30 parts of tartary buckwheat powder, 10-15 parts of mung bean powder, 10-12 parts of coix lacryma-jobi powder, 10-12 parts of glutinous rice flour, 0.1-0.3 part of flower powder, 15-20 parts of purslane, 15-20 parts of chrysanthemum nankingense, 15-20 parts of dandelion, 15-20 parts of ilex kudingcha, 15-20 parts of mulberry leaf, 15-20 parts of corn silk, 15-20 parts of cyclocarya paliurus leaf, 10-12 parts of squab soup, and 0.2-0.4 part of a flour additive. The health-care noodle is abundant in nutrition and smooth in mouthfeel, does not stick to teeth and does not muddy soup when being boiled, and is capable of regulating blood sugar, improving blood circulation, improving insulin activity and accelerating glycometabolism after being frequently eated.

A feungreek extract containing the common saponin of feungreek for preventing and treating diabetes and its chronic complications is prepared through extracting with alcohol, macroreticular adsorption, washing for removing impurities, eluting, concentrating the eluting liquid, and drying.

The invention relates to an enteric material coated chitosan nanoparticle which covers insulin and cell-penetrating peptide Tat and a preparation method of the chitosan nanoparticle. The chitosan nanoparticle is prepared from an enteric material, namely Eudragit S100, insulin, cell-penetrating peptide and chitosan. With the oral administration of the prepared enteric coated insulin chitosan nanoparticle, the amount of loaded contents released from the chitosan nanoparticle in the stomach and the upper part of the small intestine can be greatly reduced due to the protective effect of the enteric material, namely Eudragit S100. As the chitosan nanoparticle arrives at the lower end of the digestive tract, the enteric coating material on the surface of the chitosan nanoparticle begins to dissolve and the chitosan nanoparticle becomes exposed with the increase of pH value; the chitosan nanoparticle is damaged under a weakly alkaline condition, so that the cell-penetrating peptide and the insulin therein are released. The cell-penetrating peptide is capable of prompting the absorption of colonic epithelial cells to the insulin so as to improve the bioavailability of the insulin through oral administration.

The invention discloses an insulin oral nano-preparation and a preparation method thereof. Polymer sulfhydrylated hyaluronic acid with biocompatibility and bio-adhesion is adopted as a carrier to prepare an insulin-entrapped nano-suspension, and a lyophilized preparation is finally prepared. According to the method, the bio-adhesive material sulfhydrylated hyaluronic acid is firstly used as the carrier to prepare sulfhydrylated hyaluronic acid nano-particles, the insulin oral bioavailability can be improved by the preparation, and the preparation has the characteristic of excellent stability, is easy to store and transport, is convenient for patient using, and is a preparation with wide development prospect.

The invention provides a cyclocarya paliurus preparation and a preparation method thereof. The preparation can be easily and quantificationally administrated and the mouth feel of the preparation is acceptable to people who do not like to drink cyclocarya paliurus tea. The cyclocarya paliurus preparation is suitable for fat people of over 40 years in age, people having the family history of diabetes, people having hyperglycemia at one time, pregnant women of over 30 years in age and having fetal macrosomia delivery at one time, people having hyperglycemia accompanied with dysarteriotony and dyslipidemia, people having two symptoms out of hypeluricemia, hyperviscosily and hyperinsulinism, people who do not participate in manual labour all the year round, and people of valetudinarianism and hypoimmunity.

The invention relates to a marine oligosaccharide compound with type II diabetes resisting activity, which is a compound which is formed by following steps: taking D-polymannose aldehydic oligosaccharide which comes from sea and contains carboxyl in each oligosaccharide ring, reacting with dilute alkali and chromium salt solution and introducing trivalent chromium ions which is closely relative tothe generation and the development of diabetes into oligosaccharide molecules. A pharmacological experiment proves that the product has remarkable effect on accelerating insulin secretion, is not influenced by amylin and has effects on lightening glucose load, improving blood-lipoid metabolism, insulin sensitivity and certain kidney protection and lightening pancreatic injury for type II diabetesrats and mouse. The product of the invention comes from marine natural species, has the advantages of good security, unique structure, low molecular weight, high chromium binding ratio, good oral absorption effect, and the like, can play a hypoglycemic role in a plurality of links and has favorable market application prospect on the aspect of preventing and treating type II diabetes.

The invention relates to application of diosmetin in preparation of a medicine used for treating type 2 diabetes mellitus. Researches show that diosmetin can obviously improve glycometabolism of the type 2 diabetes mellitus, can improve insulin level and lower blood lipid level, can be used for preparing a blood-glucose-lowering medicine and provides a new medicine for treatment of the type 2 diabetes mellitus, thereby having significance on the treatment of diabetes mellitus.

The invention discloses application of dioscin in preparing a medicament for preventing and treating diabetes mellitus. According to the invention, the effects of dioscin in reducing blood-sugar content of various hyperglycemia models (I-type diabetes mellitus, II-type diabetes mellitus and acute hyperglycemia caused by adrenaline) and increasing the glycogen content of the hyperglycemia models are discovered, and the effects of the dioscin in improving the cell insulin resistance caused by high insulin, reducing contents of total cholesterol, triglyceride and low-density lipoprotein, increasing content of high-density lipoprotein and regulating fat metabolism disorder are simultaneously discovered, so that the application of the dioscin in preparing the medicament for preventing and treating the diabetes mellitus is invented. Various preparations prepared from the dioscin serving as a raw material according to pharmaceutically related requirement and clinical requirement can be applied clinically, and have the advantages of safety (no toxic or side effect), convenience, economy and the like.

The invention is directed to the use of at least one CBx modulator wherein the CBx modulator is selected from the group consisting of CB1 agonists; CB2 agonists; CB2 partial agonists; CB2 antagonists; CB2 inverse agonists; and dually acting compounds which are both a CB1 agonist and a CB2 agonist; and mixtures thereof, as KATP channel modulator for the prophylaxis, treatment, delayed progression, delayed onset and/or inhibition of a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans. The invention further relates to methods of treating, preventing, delaying progression of, delaying onset of and/or inhibiting a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans comprising administering to a subject in need thereof an effective amount of at least one CBx modulator having KATP channel modulating properties.

The present invention relates to medicine and its production and aims at raising biological utilization of oral absorption and strengthening the stability of the preparation. The insulin spray for oral cavity contains insulin 10000-70000 U, soybean lecithin 5-50 g and propylene glycol 25-80 g as well as borneol 1.2-10g, absolute ethyl alcohol 1-15 ml and phenol 2-5 g, the rest is pH 6.8-7.8 buffering phosphate solution, in each 1000 ml of microemulsion. The preparation process includes mixing soybean lecithin with propylene glycol, borneol and ethanol solution, addition of phenol containing buffering phosphate solution, supersonic treatment to obtain emulsified oil phase, the dissolution of insulin in the buffering solution, further mixing and supersonic treatment.

The invention discloses application of geranylgeranyl diphosphate synthase (GGPPS) for treating II-type diabetes mellitus, and particularly provides application of a GGPPS antagonist in preparation of medicament for treating the II-type diabetes mellitus. The GGPPS gene and protein antagonist capable of being used for preparing sensitization medicaments is firstly disclosed. Furthermore, the GGPPS antagonist facilitates improvement on sensibility of insulin target organization on insulin, enhances treatment effects of the insulin, improves life quality of II-type diabetics, and has potential and good application prospect in the field of the II-type diabetes mellitus treatment.

The invention discloses an oral PEGylated insulin pH-sensitive naonparticle and a preparation method thereof. The naonparticle is prepared from PEGylated insulin, pH-sensitive polymer, carrier, additives and stabilizer. The preparation method of the naonparticle comprises the following steps: preparing a PEGylated insulin/pH-sensitive polymer/carrier W/O primary emulsion, dispersing the W/O primary emulsion in a stabilizer solution to form a W/O/W multiple emulsion, obtaining a crude product after the solvent volatilizes, purifying the crude product, and carrying out freeze-drying to obtain the naonparticle. The PEGylated insulin pH-sensitive naonparticle disclosed by the invention has the advantages of uniform dispersion and high medicine enveloping rate; the insulin modified by polyethylene glycol can reduce the aggregation of insulin molecules, prolong the half life in vivo, and prolong the time of blood sugar reduction effect; and the release rate of the insulin in the gastric acid environment is reduced, the release rate of the insulin in the intestinal tract environment is enhanced since the naonparticle swells, and thus, the oral PEGylated insulin pH-sensitive naonparticle has an oral application value.

The present invention relates to a Chinese medicine composition for curing female high-insulin type polycystic ovary syndrome. Said Chinese medicine composition includes 11 Chinese medicinal materials of anemarrhena root, epimedium, tortoise plastron, ophiopogon tuber, lyceum berry, polygonatum root, sea horse, flowery knotweed root and others.

The invention discloses a traditional Chinese medicine composition for treating diabetes mellitus, which is prepared by the following components in parts by weight: 20 parts of radix puerariae, 10 parts of radix polygonati officinalis, 15 parts of snakegourd fruit roots, 10 parts of ophiopogon roots and 10 parts of schisandra chinensis. The traditional Chinese medicine composition is very remarkable in effect, can obviously reduce a fasting blood-glucose level of a T2DM (Type 2 Diabetes Mellitus) insulin resistance rat, can raise an insulin level, and can improve the sensibility of the model rat on insulin.

A Chinese medicine in the form of capsule, tablet or particle for treating high-insulin polycystic ovary syndrome, high-androgen amenorrhoea, etc is prepared from 14 Chinese-medicinal materials including anemarrhena rhizome, epimedium, wolfberry fruit, fleece flower root etc. Its preparing process is also disclosed.

The invention discloses a plant solid beverage and belongs to the technical field of health-care food. The plant solid beverage is produced from, by weight, 10-20 parts of rhizoma dioscoreae, 10-20 parts of rhizoma polygonati, 5-15 parts of folium mori powder, 5-15 parts of pollen pini, 3-8 parts of oat beta-glucan, 3-8 parts of ginseng, 3-8 parts of cortex cinnamomi, 3-8 parts of fructus lycii, 3-8 parts of fructus hippophae, 3-8 parts of radix pueraiae, 3-8 parts of bitter gourd, 3-8 parts of okra, 3-8 parts of glucose-based stevioside and 3-8 parts of mogroside. The compound plant solid beverage has the advantages that the compound plant solid beverage is produced from medicinal and edible traditional Chinese medicine materials and functional auxiliary materials, the mutual influence and interaction of the components allow the compound plant solid beverage to provide comprehensive nutritional support for diabetics, comprehensively supplement nutrients needed by human body cells andincrease insulin cell activity and body resistance, and the plant solid beverage can fast repair damaged blood vessel cells and regulate the intestines and the stomach.

The invention discloses a method for evaluation of high insulin type obesity gene physique. The method is characterized by simultaneously detecting and analyzing the SNPs site genotype of individual LEP gene, LEPR gene, IL-6 gene, and ADIPOQ gene to provide high insulin type obesity physique evaluation for all detection subjects. According to the method, the detection subjects can firstly get acquaintance with the gene physique condition of themselves and personal obesity potential cause before considering weight reducing by diet and exercises, so that a most suitable individualized nutrition and exercise weight-loss way can be selected to destroy various obesity gene expression patterns, thus achieving a most effective and healthy weight loss effect.

The invention discloses an insulin pump individualized configuration optimization system and method based on cloud big data, including an insulin pump, a real-time dynamic blood sugar monitoring system, a smart phone, blood sugar monitoring application software installed in the smart phone, and a cloud big data server. The system constructed by the present invention can effectively calculate each user's individual optimal insulin injection volume and injection rate through the user's personal blood glucose measurement history data stored in the cloud, and assist doctors and patients to formulate more effective diabetes treatment plans.

The present invention discloses a medicine for preventing and treating cattle and sheep flaccid paralysis diseases and relates to the technical field of agricultural breeding. Each liter of the medicine contains the following substances: 7 million-11 million units of vitamin A palmitate, 4 million-6 million units of vitamin D3 ethyl acetate, 10-30 g of vitamin E ethyl acetate, 15-25 mg of 25-hydroxycholecalciferol, 100-150 g of calcium gluconate, 500-800 mg of sodium selenite, 50-100 g of butafosfan, 2.5-6 g of adenosine triphosphate, 30-60 g of inositol, 100-150 g of an emulsifier, 20-30 g ofa co-emulsifier, 10-15 g of an antioxidant, 30-50 g of a surfactant and the balance purified water. The medicine can effectively reduce levels of stress hormones in body, increase concentration of insulin, significantly improve liver functions, and promote rapid use of energy while supplementing calcium so as to strengthen muscle functions, enhance vitality, enhance physical fitness, prevent andtreat the cattle and sheep flaccid paralysis diseases, and is high in absorption and utilization rates at the same time.

The invention discloses application of jasminum grandiflorum and jasminum grandiflorum extract in preparation of medicine for treating hyperlipidaemia, metabolic syndrome or non-alcoholic fatty liverdisease, and belongs to the field of medicine. The jasminum grandiflorum and the jasminum grandiflorum extract have the advantages that the obesity caused by high-fat and high-cholesterol food can beobviously reduced; the related glucose tolerance damage is reduced; fat content is greatly reduced, levels of triglyceride and cholesterol in serum and liver of a mouse fed with high fat and high cholesterol can be remarkably reduced, phosphorylation of Akt in an insulin signal channel can be activated, and accordingly insulin sensitivity is improved. The invention develops the medicinal application of jasminum grandiflorum and the extract thereof, and provides a new possibility for treating hyperlipidaemia, metabolic syndrome or non-alcoholic fatty liver disease.

The invention provides a mulberry fermentation product, and belongs to the technical field of biological fermentation. The preparation method comprises the following steps: by taking mulberries as a raw material, carrying out fermentation treatment on mulberry homogenate by utilizing a mixed suspension of two probiotics, namely, lactobacillus plantarum CICC24202 (Lactobacillusplantarum CICC24202) and lactobacillus brevis YM1301 (Lactobacillusbreris YM1301), so as to obtain a mulberry fermentation product. The mulberry fermentation product obtained by the invention has an obvious improvement effect on type 2 diabetes mellitus, can effectively reduce blood sugar, increase glucose tolerance, improve insulin sensitivity, improve insulin resistance, reduce fat accumulation of mice with type 2 diabetes mellitus, improve renal functions to a certain extent, relieve or treat type 2 diabetes mellitus complications, and has a good application prospect. The safety is high, the production is easy, and the quality stability is high.